Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 49

1.

Rate of Appendiceal Metastasis with Non-Serous Epithelial Ovarian Cancer in Manitoba.

Altman AD, Lefas G, Power L, Lambert P, Lotocki R, Dean E, Nachtigal MW.

J Obstet Gynaecol Can. 2017 Aug 17. pii: S1701-2163(17)30393-6. doi: 10.1016/j.jogc.2017.05.038. [Epub ahead of print]

PMID:
28826644
2.

Examining the Effects of Time to Diagnosis, Income, Symptoms, and Incidental Detection on Overall Survival in Epithelial Ovarian Cancer: Manitoba Ovarian Cancer Outcomes (MOCO) Study Group.

Altman AD, Lambert P, Love AJ, Turner D, Lotocki R, Dean E, Popowich S, Nachtigal MW.

Int J Gynecol Cancer. 2017 Oct;27(8):1637-1644. doi: 10.1097/IGC.0000000000001074.

PMID:
28704327
3.

Diagnostic and referral intervals for Manitoba women with epithelial ovarian cancer - the Manitoba Ovarian Cancer Outcomes (MOCO) study group: a retrospective cross-sectional study.

Love AJ, Lambert P, Turner D, Lotocki R, Dean E, Popowich S, Altman AD, Nachtigal MW.

CMAJ Open. 2017 Feb 7;5(1):E116-E122. doi: 10.9778/cmajo.20160100. eCollection 2017 Jan-Mar.

4.

Hormone Use After Nonserous Epithelial Ovarian Cancer: Overall and Disease-Free Survival.

Power L, Lefas G, Lambert P, Kim D, Evaniuk D, Lotocki R, Dean E, Nachtigal MW, Altman AD.

Obstet Gynecol. 2016 May;127(5):837-47. doi: 10.1097/AOG.0000000000001396.

PMID:
27054933
5.

Effect of changes in treatment practice on survival for cervical cancer: results from a population-based study in Manitoba, Canada.

Kang YJ, O'Connell DL, Lotocki R, Kliewer EV, Goldsbury DE, Demers AA, Canfell K.

BMC Cancer. 2015 Sep 22;15:642. doi: 10.1186/s12885-015-1624-z.

6.

Pure Immature Teratoma of the Ovary in Adults: Thirty-Year Experience of a Single Tertiary Care Center.

Alwazzan AB, Popowich S, Dean E, Robinson C, Lotocki R, Altman AD.

Int J Gynecol Cancer. 2015 Nov;25(9):1616-22. doi: 10.1097/IGC.0000000000000541.

7.

Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial.

Oza AM, Cook AD, Pfisterer J, Embleton A, Ledermann JA, Pujade-Lauraine E, Kristensen G, Carey MS, Beale P, Cervantes A, Park-Simon TW, Rustin G, Joly F, Mirza MR, Plante M, Quinn M, Poveda A, Jayson GC, Stark D, Swart AM, Farrelly L, Kaplan R, Parmar MK, Perren TJ; ICON7 trial investigators.

Lancet Oncol. 2015 Aug;16(8):928-36. doi: 10.1016/S1470-2045(15)00086-8. Epub 2015 Jun 23.

8.

Optimal uptake rates for initial treatments for cervical cancer in concordance with guidelines in Australia and Canada: Results from two large cancer facilities.

Kang YJ, O'Connell DL, Tan J, Lew JB, Demers A, Lotocki R, Kliewer EV, Hacker NF, Jackson M, Delaney GP, Barton M, Canfell K.

Cancer Epidemiol. 2015 Aug;39(4):600-11. doi: 10.1016/j.canep.2015.04.009. Epub 2015 May 23.

PMID:
26004990
9.

Performance measures related to colposcopy for canadian cervical cancer screening programs: identifying areas for improvement.

Decker KM, McLachlin CM, Lotocki R; Pan-Canadian Cervical Cancer Screening Network Monitoring Program Performance Working Group.

J Obstet Gynaecol Can. 2015 Mar;37(3):245-251. doi: 10.1016/S1701-2163(15)30310-8.

PMID:
26001871
10.

A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women.

Joura EA, Giuliano AR, Iversen OE, Bouchard C, Mao C, Mehlsen J, Moreira ED Jr, Ngan Y, Petersen LK, Lazcano-Ponce E, Pitisuttithum P, Restrepo JA, Stuart G, Woelber L, Yang YC, Cuzick J, Garland SM, Huh W, Kjaer SK, Bautista OM, Chan IS, Chen J, Gesser R, Moeller E, Ritter M, Vuocolo S, Luxembourg A; Broad Spectrum HPV Vaccine Study.

N Engl J Med. 2015 Feb 19;372(8):711-23. doi: 10.1056/NEJMoa1405044.

11.

Epithelial ovarian cancer: rationale for changing the one-fits-all standard treatment regimen to subtype-specific treatment.

Despierre E, Yesilyurt BT, Lambrechts S, Johnson N, Verheijen R, van der Burg M, Casado A, Rustin G, Berns E, Leunen K, Amant F, Moerman P, Lambrechts D, Vergote I; EORTC GCG and EORTC GCG Translational Research Group.

Int J Gynecol Cancer. 2014 Mar;24(3):468-77. doi: 10.1097/IGC.0000000000000089.

PMID:
24557434
12.

Quality of life of advanced ovarian cancer patients in the randomized phase III study comparing primary debulking surgery versus neo-adjuvant chemotherapy.

Greimel E, Kristensen GB, van der Burg ME, Coronado P, Rustin G, del Rio AS, Reed NS, Nordal RR, Coens C, Vergote I; European Organization for Research and Treatment of Cancer - Gynaecological Cancer Group and NCIC Clinical Trials Group.

Gynecol Oncol. 2013 Nov;131(2):437-44. doi: 10.1016/j.ygyno.2013.08.014. Epub 2013 Aug 27.

PMID:
23994107
13.

Changes in cervical cancer screening behavior for women attending Pap Test Week clinics.

Poliquin V, Decker K, Altman A, Lotocki R.

Int J Womens Health. 2013 Apr 8;5:141-8. doi: 10.2147/IJWH.S41214. Print 2013.

14.

Comparative models of cervical cancer screening in Manitoba.

DeRiviere L, Stopera S, Caeseele PV, Lotocki R.

Healthc Q. 2013;16(1):77-85.

PMID:
24863312
15.

Distribution of human papillomavirus types, cervical cancer screening history, and risk factors for infection in Manitoba.

Demers AA, Shearer B, Severini A, Lotocki R, Kliewer EV, Stopera S, Wong T, Jayaraman G.

Chronic Dis Inj Can. 2012 Sep;32(4):177-85.

16.

A phase 3 trial of bevacizumab in ovarian cancer.

Perren TJ, Swart AM, Pfisterer J, Ledermann JA, Pujade-Lauraine E, Kristensen G, Carey MS, Beale P, Cervantes A, Kurzeder C, du Bois A, Sehouli J, Kimmig R, Stähle A, Collinson F, Essapen S, Gourley C, Lortholary A, Selle F, Mirza MR, Leminen A, Plante M, Stark D, Qian W, Parmar MK, Oza AM; ICON7 Investigators.

N Engl J Med. 2011 Dec 29;365(26):2484-96. doi: 10.1056/NEJMoa1103799. Erratum in: N Engl J Med. 2012 Jan 19;366(3):284.

17.

Executive summary--performance monitoring for cervical cancer screening programs in Canada.

Screening Performance Indicators Working Group, Cervical Cancer Prevention and Control Network.

Chronic Dis Can. 2010 Dec;31(1):45.

18.

Quality of pathology reports for advanced ovarian cancer: are we missing essential information? An audit of 479 pathology reports from the EORTC-GCG 55971/NCIC-CTG OV13 neoadjuvant trial.

Verleye L, Ottevanger PB, Kristensen GB, Ehlen T, Johnson N, van der Burg ME, Reed NS, Verheijen RH, Gaarenstroom KN, Mosgaard B, Seoane JM, van der Velden J, Lotocki R, van der Graaf W, Penninckx B, Coens C, Stuart G, Vergote I.

Eur J Cancer. 2011 Jan;47(1):57-64. doi: 10.1016/j.ejca.2010.08.008. Epub 2010 Sep 16.

PMID:
20850296
19.

Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer.

Vergote I, Tropé CG, Amant F, Kristensen GB, Ehlen T, Johnson N, Verheijen RH, van der Burg ME, Lacave AJ, Panici PB, Kenter GG, Casado A, Mendiola C, Coens C, Verleye L, Stuart GC, Pecorelli S, Reed NS; European Organization for Research and Treatment of Cancer-Gynaecological Cancer Group; NCIC Clinical Trials Group.

N Engl J Med. 2010 Sep 2;363(10):943-53. doi: 10.1056/NEJMoa0908806.

20.

The Manitoba human papillomavirus vaccine surveillance and evaluation system.

Kliewer EV, Demers AA, Brisson M, Severini A, Lotocki R, Elias B, Hammond G, Wurtak G; Manitoba HPV Research Group.

Health Rep. 2010 Jun;21(2):37-42. Erratum in: Health Rep. 2010 Sep;21(3):77.

Supplemental Content

Loading ...
Support Center